Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Antti Siltanen portrait

Antti Siltanen

Analyst

Coverage

Herantis PharmaNexstimFaron PharmaceuticalsBioretecBiohitOrionModulight

Latest content

ShowingAll content types

Herantis trial progressing as planned

Analyst Comment 2025-05-14 07:43 by Antti Siltanen
Herantis Pharma

Trump vs. Big Pharma – Round One

Analyst Comment 2025-05-13 11:57 by Antti Siltanen
OrionHerantis PharmaFaron PharmaceuticalsModulight

Faron presented BEXMAB results at industry conference

Analyst Comment 2025-05-13 08:15 by Antti Siltanen
Faron Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account

Nexstim Q1'25 business review: New deliveries to Sinaptica

Analyst Comment 2025-05-06 09:30 by Antti Siltanen
Nexstim

Modulight Q1'25: Heading in the right direction

Research 2025-04-28 13:17 by Antti Siltanen
Modulight

Modulight Q1'25 preview: Order book and number of care facilities support revenue

Analyst Comment 2025-04-23 07:48 by Antti Siltanen
Modulight

Faron: Big picture of BEXMAB results starting to take shape

Research 2025-04-16 08:20 by Antti Siltanen
Faron Pharmaceuticals

Herantis H2'24: Phase Ib completion is this year's theme

Research 2025-03-07 09:39 by Antti Siltanen
Herantis Pharma

Herantis H2'24 flash comment: Trial progress and figures were as expected

Analyst Comment 2025-03-06 08:54 by Antti Siltanen
Herantis Pharma

Nexstim: Returning to the buy side after a share price decline

Research 2025-03-04 08:30 by Antti Siltanen
Nexstim
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.